Home / Health / FDA Flags Chinese Pharma Over Weight-Loss Drug Ingredients
FDA Flags Chinese Pharma Over Weight-Loss Drug Ingredients
22 Oct
Summary
- FDA flagged two Chinese manufacturers for quality control failures.
- Mould, contamination, and insect activity found at one facility.
- Inaccurate ingredient approval processes noted at another site.
The US Food and Drug Administration (FDA) has issued an import alert for two Chinese pharmaceutical manufacturers, Chengdu Shengnuo Biopharm and Nanjing Chengong Pharmaceutical. These actions follow inspections that revealed serious sanitation failures and quality control issues at facilities producing active ingredients for compounded GLP-1 weight-loss medications.
Inspectors documented extensive problems at Chengdu Shengnuo Biopharm, including black mould on equipment, contaminated floors, and significant insect activity. Employees were also observed attempting to conceal documents and dispose of product samples. At Nanjing Chengong Pharmaceutical, the focus was on ingredient verification, with reports of workers approving purchased active ingredients without adequate safety and quality reviews.
These developments have prompted concerns about the integrity of the supply chain for compounded versions of popular weight-loss and diabetes drugs like Ozempic and Mounjaro. The FDA's import alert allows for the detention of suspect products at the border, aiming to prevent shipments that violate manufacturing practice requirements from entering the US market.
Individuals using weight-loss injections are advised to obtain medications through legitimate medical channels, verify the source of their products, and avoid unverified online sellers. Consultation with healthcare professionals is recommended for any concerns regarding medication source or safety.
